cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Yolanda Handayani
Contact Email
yola.aksel@gmail.com
Phone
+6282157048069
Journal Mail Official
respirologyscience@gmail.com
Editorial Address
Jalan Cipinang Bunder No. 19, Cipinang, Pulogadung, Jakarta Timur, DKI Jakarta 13240, Indonesia
Location
Kota adm. jakarta timur,
Dki jakarta
INDONESIA
Respiratory Science
Published by Perhimpunan Dokter Paru Indonesia
ISSN : -     EISSN : 27471306     DOI : https://doi.org/10.36497/respirsci.v1i3.17
Core Subject : Health,
Health Professions Medicine & Pharmacology
Focuses on original article reviews and case reports in pulmonary and critical care medicine Scope: 1. Asthma 2. Chronic Obstructive Pulmonary Disease (COPD) 3. Lung Physiology and Sleep-Related Disorder 4. Lung Infection 5. Thoracic Oncology 6. Interstitial Lung Disease 7. Environmental Lung Disease 8. Tobacco Control 9. Occupational Pulmonary Disease 10. Pulmonary Intervention and Emergency Medicine 11. Respiratory critical care 12. Respiratory immunology and biomolecular
Arjuna Subject : Kedokteran - Kedokteran Paru dan Pernafasan
Articles 8 Documents
 1 
Search results for , issue "Vol. 4 No. 3 (2024): Respiratory Science" : 8 Documents clear
Profile of COVID-19 Patients at Arifin Achmad Hospital, Riau Province Between January 2021 and June 2021 Syaf, Syarlidina; Adrianison, Adrianison; Simanjuntak, Arya Marganda
Respiratory Science Vol. 4 No. 3 (2024): Respiratory Science
Publisher : Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/respirsci.v4i3.113

Abstract

Background: Coronavirus disease 2019 (COVID-19) is a disease caused by a new coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, previously called 2019 novel coronavirus) which was first identified in Wuhan City, Hubei Province, China. World Health Organization declared COVID-19 a global pandemic on March 12 2020 and until June 2021 there were 184 million cases with 3.9 million deaths worldwide. In Indonesia, until June 2021 there have been 2.2 million positive cases of COVID-19 and 60 thousand deaths. Method: The data collection method used in this study is a descriptive cross-sectional approach. According to the inclusion criteria, samples were collected for six months, and the results are shown as a distribution table. Results: The number of patients treated for the period from January to June 2021 totaled 1,442 people. The highest number of patients treated according to age was middle-aged (40.6%) and children (1.1%). The number of COVID-19 patients based on length of treatment from January to June was suspected (2-4 days) 28.13%, confirmed (5–45 days) 61.6%, discharged at own request 9.78%, referred 0.48%. The number of cured COVID-19 patients being treated at the Arifin Achmad Hospital in Riau Province from January to June 2021 has recovered 75.9% and died 13.7%. Conclusion: In Indonesia, until June 2021 there have been 2.2 million positive cases of COVID-19 and 60 thousand deaths. Riau Province as of June 2021 has recorded 70,520 confirmed cases and 1,931 deaths. The Arifin Achmad Pekanbaru General Hospital from March 2020 to June 2021 recorded 1,524 confirmed cases and 148 deaths.
Current Knowledge of Mycobacterium Other Than Tuberculosis (MOTT) in this Current Era: Definition, Taxonomy, and Diagnose Indriani, Sri Indah; Pratiwi, Adelia; Simatupang, Elvando Tunggul Mauliate; Simanjuntak, Arya Marganda
Respiratory Science Vol. 4 No. 3 (2024): Respiratory Science
Publisher : Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/respirsci.v4i3.122

Abstract

Globally, Pulmonary Tuberculosis (PTB) remains a health concern, with an annual increase in cases. Indonesia is the second-highest contributor to PTB cases globally, below India, which also saw an increase in cases, particularly after the COVID-19 pandemic. Nontuberculous Mycobacteria (NTM) infections contribute to the increase in PTB cases through misdiagnosis and overlapping conditions. The occurrence of changes in the composition of NTM species in the Mycobacterium genus is the premise for updating the diagnosis of NTM with several supporting examination modalities. Clinical, radiological, and microbiological criteria have been established by the American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA) for the diagnosis of NTM. The relationship between these three criteria is essential as a guideline for distinguishing infections caused by Mycobacterium tuberculosis (Mtb) from those caused by NTM.
Oxygen Therapy in Exacerbation of Interstitial Lung Disease Aritonang, Rachel S; Fachrucha, Fanny; Elhidsi, Mia; Desianti, Ginanjar Arum
Respiratory Science Vol. 4 No. 3 (2024): Respiratory Science
Publisher : Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/respirsci.v4i3.129

Abstract

Interstitial lung diseases (ILD) are a group of diseases that involve damage in the interstitial tissue, causing diffusion disorders which ultimately lead to hypoxemia. One of the conditions that aggravate hypoxemia in ILD patients is acute exacerbation. Acute exacerbation is a condition of deterioration of ILD that can occur in less than 1 month. During an acute exacerbation, there will be a worsening of the HRCT pattern with increased ground glass opacities and a worsening of the clinical picture including hypoxemia. Acute exacerbations are closely related to increased mortality rates. Oxygen administration is one of the supportive therapies that can be given to acute exacerbations. The provision of oxygen therapy is adjusted to the patient's needs using a high-flow nasal cannula, non-invasive ventilation, invasive mechanical ventilation, and extracorporeal membrane oxygenation.
Selective Beta-Blockers on Chronic Obstructive Pulmonary Disease: A Literature Review Van, An Thi Minh; Ahmad, Nawaid
Respiratory Science Vol. 4 No. 3 (2024): Respiratory Science
Publisher : Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/respirsci.v4i3.131

Abstract

Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) are usually coexisting. While beta-blockers are the indispensable management of an array of cardiovascular diseases, inhaled beta-receptor agonists are the central treatment for COPD patients. This review aims to assess the effect of beta-blockers on exacerbation rate, mortality, and quality of life among the COPD population. After the search on Cochrane Library, Pubmed, and Scopus, 15 relevant full-text articles published between 2012 and 2022 were included. We compared selective beta-blockers versus either non-users or non-selective agents. The results showed that selective beta-blockers did not increase the mortality and exacerbation rate in the COPD population and evidence on health-related quality of life is still sparse. However, more RCTs should be carried out for more precise information. 
Rehabilitation Management for Sarcopenia in Chronic Obstructive Pulmonary Disease: A Literature Review Widjanantie, Siti Chandra; Lestari, Fiona; Nusdwinuringtyas, Nury; Susanto, Agus Dwi
Respiratory Science Vol. 4 No. 3 (2024): Respiratory Science
Publisher : Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/respirsci.v4i3.136

Abstract

Chronic obstructive pulmonary disease (COPD) is a prevalent and debilitating chronic respiratory condition that not only affects the lungs but has far-reaching systemic consequences; one such consequence is the heightened risk of developing sarcopenia, a condition characterized by progressive loss of skeletal muscle mass and strength. Recent studies have highlighted the significant prevalence of sarcopenia among COPD patients, with rates ranging from 7.9% to 66.7%. This association underscores the importance of early identification and intervention to mitigate the adverse outcomes related to both conditions. Managing COPD patients with sarcopenia is fraught with challenges, primarily due to the multifaceted nature of both conditions. Sarcopenia exacerbates the decline in respiratory function and physical performance in COPD patients, complicating treatment and management strategies. The complexity is further amplified by the need for personalized treatment plans that address these conditions' pulmonary and musculoskeletal aspects. Precise assessment and re-evaluation are essential to ensure optimal outcomes and enhance physical and functional well-being. Rehabilitation for COPD patients with sarcopenia involves a multidisciplinary approach, focusing on exercise training, nutritional support, and pulmonary interventions. Pulmonary rehabilitation programs, tailored to individual patient needs and capabilities, have shown promise in improving exercise capacity, functional performance, and overall health status, thereby enhancing the quality of life for these patients.  In this literature review, we will discuss the elevated risk of sarcopenia in COPD patients, highlight the significance of rehabilitation management, and emphasize the pivotal role of precise assessment and re-evaluation in optimizing the care provided to this population.
The Role of Emergency Pleural Drainage in the Obstructive Shock in a Left Massive Hemothorax: A Case Report Lainy, Krisdianto Putra; Saputra, Charles; Bria, Januario; Wijaya, Oka; Chaerunnisa, Afina; Alvarabie, Radietya
Respiratory Science Vol. 4 No. 3 (2024): Respiratory Science
Publisher : Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/respirsci.v4i3.139

Abstract

Background: Spontaneous hemothorax is much less common, and the causes include malignancies, anti-coagulant medications, vascular ruptures, endometriosis, pulmonary infarctions, adhesions with pneumothorax, and hematologic abnormalities such as hemophilia. This report presented a confirmed case of obstructive shock in a patient with massive left hemothorax and elaborated on the role of emergency pleural drainage in this particular clinical situation. Case: Reported a case of a 56-year-old man with a 2-month history of dyspnea, leg swelling, abdominal bloating, hemoptysis, and fatigue. Physical examination revealed an asymmetrical chest wall expansion with a predominance of abdominal breathing. His neck and face were markedly discolored and swollen, with distended veins. The left hemithorax was dull on percussion and, on auscultation, significantly reduced air entry at the left lung base. Discussion: The patient was given an O2 non-rebreathing mask (NRBM) on arrival. The patient was administered two vasopressors (dopamine, 2.5 mcg/kg per body weight/minute, and norepinephrine, 0.1 mcg/kg per body weight/minute). Given the patient’s hemodynamic instability and high probability of imminent death. The patient required urgent intervention to relieve the obstructive shock. The surgical department was inserted to treat the massive hemothorax, which drained approximately 1.5 liters of blood. The patient received supplementary oxygen, antibiotics, and furosemide.­ Conclusion: The pleural fluid drainage alleviated the dyspnea. As supportive therapy, the patient received oxygen, antibiotics, and furosemide. On the follow-up, the mediastinal shift had resolved simultaneously.
Long COVID-19: Multidisciplinary Approach and Pulmonary Fibrosis Sequelae Febrina, Nidya; Yovi, Indra
Respiratory Science Vol. 4 No. 3 (2024): Respiratory Science
Publisher : Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/respirsci.v4i3.140

Abstract

COVID-19 patients may experience a persistent condition of post-COVID-19 infection, which is known as the long-COVID phenomenon or post-acute sequelae of SARS-CoV-2 infection (PASC) or post-acute COVID-19 syndrome (PACS) with long-term sequelae characteristics that stay after the convalescent period of COVID-19 disease. The most common clinical symptoms found within 5 weeks post-infection were fatigue (12.7%), cough (12.4%), headache (11.1%), loss of sense of taste or smell (10.4%), and muscle pain (8.8%). Women have a slightly higher prevalence than men, with a value of 23.6% and 20.7%, respectively, which are dominated by 35-49 years old (26.8%), 50-69 years old (26.1%), and 25-34 years old (24.9%). Pulmonary fibrosis sequelae in COVID-19 occur due to the destruction of the alveolar epithelium and the formation of active myofibroblast foci, causing excessive accumulation of extracellular matrix in lung tissue. Long COVID management requires a multidisciplinary approach, including health workers and the wider community, as well as systematic assessment management. The recommended therapy includes pharmacological (symptomatic, micronutrients, antibiotics, and anti-inflammatory) and non-pharmacological (medical and psychosocial rehabilitation). This review aims to summarize the long COVID and multidisciplinary approach to improve the patient's quality of life.
Carcinoembryonic Antigen (CEA) and Cancer Antigen 125 (CA-125) as Diagnostic Biomarkers for Malignant Pleural Effusion Harsini, Harsini; Kurniawan, Yoseph Dwi; Sutanto, Yusup Subagio
Respiratory Science Vol. 4 No. 3 (2024): Respiratory Science
Publisher : Indonesian Society of Respirology (ISR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36497/respirsci.v4i3.142

Abstract

Background: The etiology of pleural effusion is very important in malignant pleural effusion management and prognosis. Pleural fluid cytology examination is a simple diagnostic tool and has been widely used to differentiate the etiology of pleural fluid with high specificity albeit its relatively low sensitivity. The use of tumor markers for malignant pleural effusion in Indonesia is still sparse. This study was intended to determine the sensitivity and specificity of CEA and CA-125 examinations in diagnosing malignant pleural effusion. Method: This was an observational analytic study with a cross-sectional approach to find the diagnostic value of CA-125 and CEA of pleural fluid in malignant pleural effusion. Subjects were patients with suspicion of malignant pleural effusion who underwent treatment in the emergency room, polyclinic, and inpatient ward at RSDM from October - November 2022. Results: CEA value with a cutoff of ≥32.00 had a sensitivity of 83.3%; specificity of 87.8%; PPV of 90.9%; NPV of 77.8% with an accuracy of 85.0% (P=0.001), a CA-125 value with a cutoff of >152.40 had a sensitivity of 83.3%; specificity 81.3%; PPV 87.0%; NPV 76.5%; with an accuracy of 82.5% (P=0.001). An increase in CEA and CA-125 signified a significant risk of malignant pleural effusion (P<0.05). Patients with increased CEA and CA-125 had 105 times the risk of developing malignant pleural effusion. Conclusion: CEA ≥32.00 and CA-125 >152.40 are potential biomarkers to predict malignant pleural effusion with CEA having better specificity than CA-125.

Page 1 of 1 | Total Record : 8

 1 

Filter by Year

2024 2024


Reset
Filter By Issues
All Issue Vol. 6 No. 1 (2025): Respiratory Science Vol. 5 No. 3 (2025): Respiratory Science Vol. 5 No. 2 (2025): Respiratory Science Vol. 5 No. 1 (2024): Respiratory Science Vol. 4 No. 3 (2024): Respiratory Science Vol. 4 No. 2 (2024): Respiratory Science Vol. 4 No. 1 (2023): Respiratory Science Vol. 3 No. 3 (2023): Respiratory Science Vol. 3 No. 2 (2023): Respiratory Science Vol. 3 No. 1 (2022): Respiratory Science Vol. 2 No. 3 (2022): Respiratory Science Vol. 2 No. 2 (2022): Respiratory Science Vol. 2 No. 1 (2021): Respiratory Science Vol. 1 No. 3 (2021): Respiratory Science Vol. 1 No. 2 (2021): Respiratory Science Vol. 1 No. 1 (2020): Respiratory Science More Issue